Plain-English translation of NCT06522594 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication that slows the heart rate, can safely help patients with severe heart failure who are on a special life-support machine called V-A ECMO. The machine does the work of the heart and lungs, giving doctors a chance to try treatments that might help the heart recover. The researchers want to see if this medication can help the heart heal by reducing stress on it.
Many patients on this life-support machine cannot recover their heart function or come off the machine, and survival rates are low. Doctors believe that by reducing how hard the heart has to work—using this medication—they might give the heart a better chance to heal and improve survival.
If you join this trial, doctors will gradually reduce your current heart-stimulating medications and start giving you through an IV, slowly increasing the dose over several hours to reach your target heart rate between 50 and 70 beats per minute. The team will monitor your heart closely with frequent check-ups and adjustments before each dose increase. This medication phase will continue for 48 hours after you are enrolled, or earlier if your doctors decide it is necessary to stop.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
Netherlands